AbbVie
1 North Waukegan Road
North Chicago
Illinois
60064
United States
Tel: 1-800-255-5162
Website: http://www.abbvie.com/
Email: customerservice@abbvie.com
About AbbVie
AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, and YouTube.
Stock Symbol: ABBV
Stock Exchange: NYSE
We’re a company that takes on the toughest health challenges. But we do more than treat diseases—we aim to make a remarkable impact on people’s lives. We are AbbVie, a highly focused research-driven biopharmaceutical company.
1367 articles with AbbVie
-
AbbVie Presents Integrated Efficacy and Safety Data From Two Phase 3 Trials on Risankizumab (SKYRIZI®) in Psoriatic Arthritis at ACR Convergence 2021
11/5/2021
AbbVie (NYSE: ABBV) today announced the presentation of integrated data from two Phase 3 clinical trials, KEEPsAKE 1 and KEEPsAKE 2, evaluating the efficacy and safety of risankizumab (SKYRIZI®) in adult patients with active psoriatic arthritis (PsA).
-
AbbVie to Highlight New Advances in Blood Cancer Research and Expanding Oncology Pipeline at 63rd ASH Annual Meeting
11/4/2021
AbbVie will present results from nearly 30 abstracts across eight types of cancer during the upcoming American Society of Hematology Annual Meeting in Atlanta, Georgia.
-
AbbVie Highlights Innovative Research From Its Rheumatology Portfolio at ACR Convergence 2021
11/1/2021
Thirty-eight abstracts underscore AbbVie's commitment to advancing its portfolio of medicines to help more people living with rheumatic diseases
-
The decision made VUITY the very first and only eye drop to be approved for the Presbyopia treatment. Follow the article to know aspects of this new treatment.
-
Clinical Catch-Up: October 25-29
11/1/2021
Yet another busy week for clinical trial news. Here’s a look. -
AbbVie's Cariprazine (VRAYLAR®) Met Primary Endpoint in Phase 3 Study as an Adjunctive Treatment for Major Depressive Disorder
10/29/2021
- In a Phase 3 clinical trial, Study 3111-301-001, cariprazine (VRAYLAR®) met its primary endpoint demonstrating statistically significant change from baseline to week six in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score in patients with major depressive disorder
-
AbbVie Reports Third-Quarter 2021 Financial Results
10/29/2021
AbbVie (NYSE:ABBV) announced financial results for the third quarter ended September 30, 2021.
-
U.S. Food and Drug Administration Approves VUITY™ (pilocarpine HCI ophthalmic solution) 1.25%, the First and Only Eye Drop to Treat Presbyopia (Age-Related Blurry Near Vision)
10/29/2021
Allergan, an AbbVie company, announced the U.S. Food and Drug Administration approval of VUITY™ 1.25% for the treatment of presbyopia, commonly known as age-related blurry near vision, in adults.
-
After first reporting that its investigational RNAi drug vutrisiran hit its 9-month Phase III endpoints, Alnylam announced it continues to demonstrate positive results at the 18-month mark.
-
AbbVie Announces ABBV-951 (Foslevodopa/Foscarbidopa) Showed Improvement in Controlling Motor Fluctuations Compared to Oral Levodopa/Carbidopa Medication in Pivotal Phase 3 Trial in Patients with Advanced Parkinson's Disease
10/28/2021
AbbVie today announced that continuous 24 hours/day subcutaneous infusion of ABBV-951 was statistically superior to oral levodopa/carbidopa in reducing motor fluctuations in patients with advanced Parkinson's disease (PD) in a Phase 3, randomized, double-blind, double-dummy, active-controlled study.
-
The U.S. FDA greenlit a new indication for Gilead Sciences’ drug Biktarvy for pediatric patients with HIV who are virologically suppressed or new to antiretroviral therapy.
-
AbbVie Receives CHMP Positive Opinion for Risankizumab (SKYRIZI®) for the Treatment of Adults with Active Psoriatic Arthritis in the European Union (EU)
10/15/2021
AbbVie (NYSE: ABBV) today announced the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended the approval of risankizumab (SKYRIZI®, 150 mg, subcutaneous injection at week 0, week 4 and every 12 weeks thereafter) alone or in combination with methotrexate (MTX).
-
AbbVie's Upadacitinib (RINVOQ®) Met Primary and Most Ranked Secondary Endpoints in Phase 3 Study for Non-Radiographic Axial Spondyloarthritis
10/7/2021
- In Study 2 of the Phase 3 SELECT-AXIS 2 clinical trial, upadacitinib (RINVOQ®) met the primary endpoint of ASAS40 at week 14 versus placebo (45 percent compared to 23 percent)[1]
-
AbbVie's RINVOQ® (upadacitinib) Met Primary and All Ranked Secondary Endpoints in Phase 3 Study in Ankylosing Spondylitis
10/7/2021
- In Study 1 of the Phase 3 SELECT-AXIS 2 clinical trial, RINVOQ® (upadacitinib) met the primary endpoint of ASAS40 at week 14 versus placebo (45 percent compared to 18 percent) in patients with ankylosing spondylitis and inadequate response to bDMARD therapy[1]
-
AbbVie to Host Third-Quarter 2021 Earnings Conference Call
10/5/2021
AbbVie (NYSE: ABBV) will announce its third-quarter 2021 financial results on Friday, October 29, 2021 , before the market opens.
-
AbbVie to Showcase New Data at the United European Gastroenterology (UEG) Week Virtual 2021
10/2/2021
AbbVie announced new data on the investigational use of risankizumab in Crohn's disease, upadacitinib in ulcerative colitis and HUMIRA® in inflammatory bowel disease will be presented as live presentations and e-Posters at the United European Gastroenterology Week Virtual 2021, to be held October 3-5.
-
AbbVie Presents Late-Breaking Data on Risankizumab (SKYRIZI®) in Psoriatic Arthritis at the 30th European Academy of Dermatology and Venereology (EADV) Congress
9/30/2021
AbbVie (NYSE: ABBV) today presented results from new Phase 3 data analyses of KEEPsAKE-1 and KEEPsAKE-2, evaluating risankizumab (SKYRIZI®, 150 mg) in adults with active psoriatic arthritis for one year (52 weeks).
-
AbbVie Presents New Analyses Evaluating RINVOQ® (upadacitinib) in Atopic Dermatitis Across Patient Characteristics and Body Regions at EADV Virtual Congress
9/30/2021
AbbVie (NYSE: ABBV) today announced new analyses from the Phase 3 RINVOQ® (upadacitinib) atopic dermatitis clinical trial program to be presented at the 30th European Academy of Dermatology and Venereology (EADV) Virtual Congress.
-
Teva Pharmaceuticals reached a $15 million agreement with the state of Louisiana to settle claims against the company over its marketing of opioid products.
-
Biomolecular condensates could hold the key to unlocking a number of neurological diseases that have baffled researchers the longest.